Roferon A (recombinant interferon alfa-2a) / Roche - LARVOL DELTA

Therapeutic difficulties in the treatment of a girl with primary hypoparathyroidism (ESPE-ESE 2025) - "Although primary hypoparathyroidism is a rare endocrinopathy in children, it often causes therapeutic difficulties, as there is no standard hormone replacement therapy."

Cardiovascular • CNS Disorders • Endocrine Disorders • Epilepsy • Hypoparathyroidism • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Metabolic Disorders • Nephrology • Pediatrics • Pneumonia • Primary Immunodeficiency • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus • IFNA1 • IL17A • IL22

Prognostic Factors of Treatment Failure with First-Line Corticosteroid-Sparing Agents in Patients with Birdshot Chorioretinopathy: A Retrospective Study. (PubMed, Ocul Immunol Inflamm) - "First-line treatment consisted in oral corticosteroids (prednisone) and mycophenolate mofetil (MMF) or interferon alpha-2a (IFN). Second-line treatment consisted in biologics, i.e. anti-TNFα or tocilizumab (TCZ)...Among 11 patients treated sequentially with MMF, anti-TNFα and TCZ, mean prednisone dose significantly decreased with anti-TNFα compared to MMF (13.2 vs 21.9 mg/day, p = 0.002), TCZ compared to MMF (5.7 vs 21.9, p < 0.001) and TCZ compared to anti-TNFα (5.7 vs 13.2, p = 0.001). At baseline, clinical papillitis, angiographic papillary leakage, RNFL thickness and mean deviation could be prognostic factors of treatment failure with first-line corticosteroid-sparing agents in patients with BCR."

Biomarker • Journal • Retrospective data • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Comment on: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis: reply. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • Immunology • Scleroderma • Systemic Sclerosis

Comment On: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • Immunology • Scleroderma • Systemic Sclerosis

Idiopathic Photoreceptoritis: An Unusual Variant of Outer Retinopathy. (PubMed, Ocul Immunol Inflamm) - "Despite oral valaciclovir, the disease progressed rapidly, prompting referral to a tertiary care center...Given the temporal association with the herpetic infection and the sight-threatening progression, treatment was escalated to intravenous acyclovir and subsequently foscarnet for 2 weeks, which slowed down disease progression...The disease was stabilized with antiviral therapy, while structural recovery of the photoreceptors was achieved through anti-inflammatory and immunosuppressive treatments. This report underscores the importance of a multidisciplinary approach to managing atypical retinal inflammatory disorders."

Journal • Infectious Disease • Inflammation • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Successful management of large conjunctival squamous cell carcinoma with excisional biopsy, topical interferon, and amniotic membrane grafting: A case report. (PubMed, Int J Surg Case Rep) - "A multidisciplinary treatment strategy can effectively manage advanced conjunctival SCC, as seen in this case, where no recurrence occurred after one year of follow-up. Early detection and comprehensive care are essential for positive outcomes."

Journal • Oncology • Ophthalmology • Squamous Cell Carcinoma

Recurrence rate of corneal squamous cell carcinoma in dogs undergoing superficial keratectomy surgery. (PubMed, Open Vet J) - "Dogs with chronic corneal inflammatory conditions, particularly brachycephalic breeds, are at higher risk for developing cSCC. Corneal SCC should be suspected in middle-aged brachycephalic dogs presenting with proliferative, raised, or hyperaemic corneal lesions."

Journal • Retrospective data • Keratitis • Ocular Inflammation • Oncology • Squamous Cell Carcinoma

Successful checkpoint inhibition in a patient with metastatic melanoma and advanced Sézary syndrome (ADO 2024) - "These include PUVA, MTX, Roferon, mogamulizumab, brentuximab, bexarotene, all of which were combined with extracorporeal photopheresis (ECP) that had been performed for several years...The adjuvant therapy with pembrolizumab that had already been initiated was not continued after the decision of the interdisciplinary lymphoma board due to insufficient data and the fear of hyperprogression of the SS after one cycle...After consultation in the interdisciplinary tumor board decision, the patient received combined immunotherapy with ipilimumab and nivolumab (3 and 1m kg body weight q3w, respectively) as well as stereotactic radiation (ED/GD 20Gy). Mogamulizumab was stopped and ECP continued. We report on the further course, the encouraging response and the overall good tolerability of this therapy both with regard to the metastatic melanoma and the SS."

Checkpoint inhibition • Clinical • Metastases • Cutaneous Melanoma • Cutaneous T-cell Lymphoma • Dermatopathology • Melanoma • Oncology • Sezary Syndrome • Solid Tumor • CD4 • CD8

Cyclosporin A as an adjunct may enhance the therapeutic effect of interferon alpha-2a in patients with refractory Behcet's uveitis: a retrospective cohort study. (PubMed, Ther Adv Chronic Dis) - "Overall, the frequency of uveitis relapse and the dose of oral prednisolone were significantly reduced in both groups after treatment (all p < 0.0001)...IFN-α2a treatment is a promising option for patients with refractory BU. Our results showed that cyclosporin A as an adjunct could enhance the therapeutic effect of IFN-α2a."

Journal • Retrospective data • Immunology • Ocular Inflammation • Ophthalmology • Rare Diseases • Uveitis • IFNA1

Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis. (PubMed, Rheumatology (Oxford)) - "Using serum determinations, the activation of the T1 IFN pathway showed strong correlations with inflammatory mediators and associations with clinical manifestations, especially skin fibrosis and ILD in SSc patients. However, activated IFN pathway was not predictive of ILD progression."

Journal • Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • CCL19 • CCL8 • CXCL10 • CXCL11 • IFNA1

A puzzling case of Angiolymphoid Hyperplasia with Eosinophilia: diagnosis and management challenges (EADV 2024) - "Other treatment options are pulsed-dye laser, CO2 laser, cryosurgery, systemic or intralesional corticotherapy, imiquimod, tacrolimus, isotretinoin, interferon alfa2a, anti-IL-5 antibodies, or dupilumab. Oral propranolol might be of use in selected patients. ALHE is a rare disease but it has characteristic histopathological findings that can help the diagnosis. There are a large variety of proposed treatments but not enough data on most of them. Surgical excision is the treatment of choice in forms with fewer lesions."

Clinical • Angiosarcoma • Eosinophilia • Hematological Malignancies • Hepatology • Lymphoma • Oncology • Rare Diseases • Sarcoma • Solid Tumor • IL5

The importance of IFNα2A (Roferon-A) in HSV-1 latency and T cell exhaustion in ocularly infected mice. (PubMed, PLoS Pathog) - "The absence of IFNα2A significantly reduced the levels of latency and T cell exhaustion but not time of reactivation compared with control mice. Our results suggest that blocking IFNα2A expression may be a useful tool in reducing latency and the subsequent side effects associated with higher levels of latency."

Journal • Preclinical • Infectious Disease • Ocular Infections • Oncology • Ophthalmology • IFNA1 • IFNB1 • IFNG

Have you considered Human Papillomavirus(HPV) vaccine in the treatment of Epidermodysplasia Verruciformis disease? (EADV 2024) - "EV therapy includes UV exposure protection, topical imiquimod, oral isotretinoin, and intralesional interferon alfa, but patients are often resistant to these treatments(2)... If we refer to the efficacy of the vaccine in cutaneous carcinomas, in a study conducted by Nika et al.in 2015, HPV- 32 was isolated in a patient with recurrent squamous cell papilloma resistant to treatments and quadrivalent HPV vaccine was administered, and almost complete regression was observed in the lesions after about three months. The production of cross-protective immunoglobulins and cytotoxic T cells has been considered as a possible mechanism(3). In a study published by Nichols et al."

Actinic Keratosis • Dermatology • Genetic Disorders • Human Papillomavirus Infection • Infectious Disease • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial. (PubMed, Lancet Rheumatol) - "Adalimumab plus corticosteroids was superior to ciclosporin plus corticosteroids with respect to uveitis relapse rate in patients with severe Behçet's disease naive to anti-TNF therapy, and interferon alfa-2a plus corticosteroids was not found to be non-inferior to adalimumab plus corticosteroids or superior to ciclosporin plus corticosteroids."

Head-to-Head • Immunomodulating • Journal • Ocular Inflammation • Ophthalmology • Rare Diseases • Uveitis

LONG TERM FOLLOW-UP OF HAIRY CELL LEUKEMIA TREATMENT: 30-YEAR EXPERIENCE AT SINGLE UNIVERSITY CENTER (EHA 2024) - "Background: Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis following cladribine(2CDA) treatment, even though relapse may occur during course of disease...1% at the time of evaluation with first, second and third remissionmedian of 49, 73 and 83 months respectively which could be explained with adding rituximab in subsequenttreatments... The most important risk factors for relapse after one TL of 2CDA were younger age and SM. We registered riskfactors for SM occurrence during the course of HCL to be age and Interferon treatment. Younger patientsdevelop more relapses with consecutive more frequent number of TL."

Cardiovascular • Congestive Heart Failure • Hairy Cell Leukemia • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Oncology • Solid Tumor

Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules. (PubMed, AIDS) - "Obatoclax and other Bcl-2 inhibitors deserve further study in combination therapies aimed at reducing the intact HIV reservoir in order to achieve a functional cure and/or reduce HIV-associated immune activation."

Journal • Human Immunodeficiency Virus • Infectious Disease • IFNG

Protein profiles in the transfected oviductal secreting cells of laying hen (Gallus gallus domesticus). (PubMed, Poult Sci) - "According to the bioinformatic analyses there was a limited negative impact of transfection on cells, and the normal biochemical pathways were not severely disordered. In conclusion, the observations provide new knowledge about the proteomic profile of the manipulated COEC with regard to the retained normal functionality of the cells, which can be informative for avian biopharma research."

Journal • Rare Diseases • IFNA1

Differential susceptibility of cells infected with defective and intact proviruses to HIV-selective cell killing by small molecule therapies (IAS-HIV 2023) - " We tested drugs currently in clinical use or human trials, including interferon alpha2A, interferon gamma, acitretin (RIG-I inducer), GS-9620/vesatolimod (TLR7 agonist), nivolumab (PD-1 blocker), auranofin (p53 modulator), obatoclax (Bcl-2 inhibitor), FX-1 (Bcl-6 inhibitor), bortezomib (proteasome inhibitor), birinapant (IAP inhibitor), and INK128/sapanisertib (mTOR[c]1/2 inhibitor)... Several drugs induced selective ex vivo depletion of cells with intact proviruses (obatoclax, possibly auranofin, INK128, and bortezomib) or defective proviruses (vesatolimod). Their distinct modes of action on cell death/survival and innate immune response provide a strong rationale to compare the effects of drug combinations ex vivo and in animal or human trials."

Human Immunodeficiency Virus • Infectious Disease • BCL6 • IFNA1 • IFNG • IL2

Expression and purification of human interferon alpha 2a (IFNα2a) in the methylotrophic yeast Pichia pastoris. (PubMed, Protein Expr Purif) - "The biological activity of the P. pastoris-produced IFNα2a was confirmed in A549 and HT29 cells by monitoring transcriptional up-regulation of a panel of known interferon-stimulated genes (ISGs). Our results document that the P. pastoris expression system is a suitable system for producing biologically functional IFNα2a in a secreted form."

Journal • Chronic Myeloid Leukemia • Genito-urinary Cancer • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • IFNA1

PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY (EHA 2023) - P1/2 | "Preliminary results from Arm 4 of the MANIFEST study suggest potential clinical benefit with PELA monotherapy in pts with HR ET refractory or intolerant to HU as supported by hematologic responses and symptom improvement. Safety data suggest a tolerable and manageable safety profile. Mutation data and other pharmacodynamic analyses indicate potential biomarker changes after PELA monotherapy."

Clinical • Monotherapy • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytopenia • Thrombocytosis • BDNF • CALR • CXCL8 • DKK1 • JAK2 • MMP1 • MMP9 • TIMP3

Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study. (ASCO 2023) - P1/2 | "Preliminary results from Arm 4 of the MANIFEST study suggest potential clinical benefit with PELA monotherapy in pts with HR ET refractory or intolerant to HU as supported by hematologic responses and symptom improvement. Safety results are consistent with the known safety profile of PELA and as expected in the underlying study population. Clinical trial information: NCT02158858."

Monotherapy • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Thrombocytopenia • Thrombocytosis

Management of osteoporosis in patients with systemic mastocytosis: a monocentric expert centre experience (EULAR 2023) - "One patient from the MIDO group and 1 patient from the MASI group were concomitantly exposed to bisphosphonates (respectively alendronate and zoledronate)...Conclusion Our data show that monthly pamidronate, and combination of interferon & pamidronate improve BMD and may reduce fracture risk over 1 year in SM. Conversely, our data do not support the use of interferon monotherapy or midostaurin as preferred strategy in patients with severe osteoporosis. Usefulness of masitinib, and of recent tyrosine kinase inhibitors needs further studies in this population."

Clinical • Hematological Disorders • Hematological Malignancies • Musculoskeletal Diseases • Oncology • Orthopedics • Osteoporosis • Rheumatology

The BioBehçet’s Trial: Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment (EULAR 2023) - P3 | "Metabolomic analysis identified potential markers for response to treatment with infliximab. Conclusion We report an equivalent efficacy between infliximab and Roferon in refractory active BS, better tolerability of Roferon compared to that anticipated, together with the potential for a novel metabolomic biomarkers identifying a clinical response to infliximab."

Clinical • Immunology • Musculoskeletal Pain • Pain • Rare Diseases • Rheumatology • IFNL3

Relentless placoid chorioretinitis: A review of four cases in pediatric and young adult patients with a discussion of therapeutic strategies. (PubMed, Front Pediatr) - "One patient did not require a steroid-sparing agent after oral prednisone taper as there was no evidence of progression or recurrence...In this case study, relapses of RPC were found among patients on mycophenolate mofetil and interferon-alpha-2a, and one case did not relapse on oral steroids without a steroid-sparing agent. Our findings suggest that adalimumab, infliximab, and tocilizumab may be useful medications to obtain quiescence of RPC."

Journal • Review • Genetic Disorders • Ocular Inflammation • Ophthalmology • Pediatrics • Retinal Disorders • Uveitis

Erdheim-Chester disease with chorioretinal and orbital involvement: a case report. (PubMed, Arq Bras Oftalmol) - "The same therapy was administered, and her clinical condition improved. The Erdheim-Chester disease is a rare chronic histiocytic proliferative disease that requires a multidisciplinary approach and can be fatal if left untreated because of multisystemic involvements."

Journal • Pain • Rare Diseases • BRAF • IFNA1